Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer

Exclusion Criteria

• •Received at least 1 prior regimen with oxaliplatin for metastatic disease
• •Recurrent disease following prior adjuvant therapy allowed
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-1
• •Granulocyte count ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Creatinine normal
• •Bilirubin normal
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception duration and for 3 months after completion of study treatment
• •No known Gilbert's disease or other chronic liver disease
• •No colonic or small bowel disorders (e.g., inflammatory bowel disease, Crohn's disease, or ulcerative colitis) that predispose the patients to uncontrolled diarrhea (i.e., \> 3 watery or soft stools daily at baseline in patients without a colostomy or ileostomy)
• •PRIOR CONCURRENT THERAPY:
• •See Disease Characteristics
• •Recovered from prior therapy
• •No prior irinotecan
• •Prior pelvic radiotherapy allowed as long as measurable lesion is outside irradiated field
• •No concurrent palliative radiotherapy
• •No other concurrent chemotherapy
• •No concurrent steroids except those given for adrenal failure, hormones for non-disease-related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an antiemetic or for prevention of infusion reaction